568 related articles for article (PubMed ID: 28098353)
21. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
22. PPAR ligands: are they potential agents for cardiovascular disorders?
Balakumar P; Rose M; Singh M
Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
[TBL] [Abstract][Full Text] [Related]
23. PPARs as targets for metabolic and cardiovascular diseases.
Cheng PT; Mukherjee R
Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
Patsouris D; Müller M; Kersten S
Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor ligands in atherosclerosis.
Viles-Gonzalez JF; Choi BG; Fuster V; Badimon JJ
Expert Opin Investig Drugs; 2004 Nov; 13(11):1393-403. PubMed ID: 15500388
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptors as attractive antiobesity targets.
Zhang F; Lavan B; Gregoire FM
Drug News Perspect; 2004 Dec; 17(10):661-9. PubMed ID: 15696231
[TBL] [Abstract][Full Text] [Related]
27. A new insight into the treatment of diabetes by means of pan PPAR agonists.
Chandra A; Kaur P; Sahu SK; Mittal A
Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085
[TBL] [Abstract][Full Text] [Related]
28. PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
[TBL] [Abstract][Full Text] [Related]
29. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
30. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
Guan Y
Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
O'Sullivan SE
Br J Pharmacol; 2007 Nov; 152(5):576-82. PubMed ID: 17704824
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
33. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
34. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
Menendez-Gutierrez MP; Roszer T; Ricote M
Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
[TBL] [Abstract][Full Text] [Related]
35. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
[TBL] [Abstract][Full Text] [Related]
36. Examining the safety of PPAR agonists - current trends and future prospects.
Bortolini M; Wright MB; Bopst M; Balas B
Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
[TBL] [Abstract][Full Text] [Related]
37. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
38. PPAR agonists and the metabolic syndrome.
Staels B
Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
[TBL] [Abstract][Full Text] [Related]
39. Beneficial health effects of Chios Gum Mastic and peroxisome proliferator-activated receptors: indications of common mechanisms.
Georgiadis I; Karatzas T; Korou LM; Katsilambros N; Perrea D
J Med Food; 2015 Jan; 18(1):1-10. PubMed ID: 25133901
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
